Kornimate/medical-research-clean huggingface dataset:
pancreaticobiliary reflux in patients without cholelithiasis

Conditions: Pancreaticobiliary Reflux

Summary: pancreaticobiliary reflux has been found in patients with cholelithiasis and gallbladder cancer associated with normal pancreaticobiliary union. however, the presence of pancreaticobiliary reflux has not been studied in patients without gallstones (healthy gallbladders). the authors believe that pancreaticobiliary reflux might be a normal phenomenon in patients with and without gallstones, although in patients with cholelithiasis it might constitute a pathological condition associated with dismotility of the biliary tree and the sphincter of oddi.

the objective of this study is to measure the levels of amylase and lipase in gallbladder bile of patients without gallstones and compare these values to the values of amylase and lipase of patients with gallstones and normal pancreaticobiliary union evidenced by intraoperative cholangiography.

Eligibility criteria:
inclusion criteria: * age older than 15 years of age * elective surgery * normal intraoperative cholangiography * normal preoperative serum amylase and lipase values exclusion criteria: * common bile duct stones * anatomic anomalies at the pancreaticobiliary junction evidenced by intraoperative cholangiography * altered preoperative amylase and lipase levels * altered preoperative hepatic function tests * emergency surgery

Keywords: pancreaticobiliary reflux normal pancreaticobiliary junction gallstones cholelithiasis cholecystectomy
exploration of tumor accumulation of bay94-9392 in patients with cancer

Conditions: Neoplasms

Summary: the study will be conducted as an open label, single-dose, explorative study with patients with histologically proven cancer and, preferably, tumor positive lesions in previously performed nuclear medicine imaging examinations. the investigational drug will be given as a single administration in a dose of \</= 0.1 mg bay94-9392 (300 mbq, +/- 10%). the total duration of the study for each patient will be approximately 8 days.


Eligibility criteria:
inclusion criteria: * males/females \>/= 18 years * patients with a diagnosis of primary prostate cancer (biopsy proven) and scheduled for radical prostatectomy or patients with prostate tumor recurrence (patients with advanced tumor disease and a high likelihood to display lymph node metastasis are to be preferably included.) * ecog (eastern cooperative oncology group) performance status of 0-2, determined within one week prior to treatment with bay94-9392 * patient had an \[18f\]-fluorodeoxyglucose (fdg) pet/ct for detection, or staging, or restaging, or therapy response assessment that still showed tumor mass with high certainty for a cancer such as melanoma, or colorectal cancer, or head \& neck cancer for which fdg-pet/ct is used in clinical routine, and the primary cancer disease is histologically confirmed. in case of recurrent disease confirmation of the primary tumor is sufficient * no clinically relevant deviations in renal function as determined by cockcroft and gault method using serum creatinine at screening. exclusion criteria: * concurrent severe and/or uncontrolled and/or unstable medical disease other than cancer or inflammation (e.g. poorly controlled diabetes, congestive heart failure, myocardial infarction within 12 months prior to planned injection of bay94-9392, unstable and uncontrolled hypertension, chronic renal or hepatic disease, severe pulmonary disease) which could compromise participation in the study * known sensitivity to the study drug or components of the preparation * previous treatment with bay94-9392 in this study

Keywords: prostatic neoplasms colorectal neoplasms head and neck neoplasms melanoma neoplasm metastasis
interactions between drug effects and environments ii

Conditions: Substance-Related Disorders

Summary: the purpose of the study is to determine how associations between drugs and the places where they are experienced influence drug seeking, mood and acute drug responses.

learned associations between drug effects and the people, places, and paraphernalia (cues) linked with drug experiences are a major barrier to the treatment of drug addiction. these links are remarkably persistent and can cause relapse to drug taking even after long periods of abstinence. they are also key features in some of the foremost theories of addiction, yet there is little clinical evidence of how these associations are formed and how they come to profoundly control behavior. the long-term goal of this research is to understand how drug cues become powerfully linked with drug experiences and their influence on mood and behavior. in the proposed project, the investigators will use a de novo conditioning paradigm to examine the influence of drug contexts on drug seeking, mood and acute drug responses. the hypothesis is that drug-paired contexts gain motivational salience, induce approach, and alter acute subjective responses to the drug.this knowledge will lead to novel treatment strategies to counteract the effects of drug cues on mood and behavior, and also to prevent relapse.

Eligibility criteria:
inclusion criteria: * past use of stimulants * bmi 19-26 * hormonal birth control for women exclusion criteria: * current or recent (past year) history of major axis i disorder

Keywords: drug cues
use of desferal for prevention of ards in hospitalised cases documented with covid 19 infection

Conditions: Covid 19

Summary: to evaluate the efficacy of using desferal injections for prevention of ards in moderate cases with fever , chest tightness and relevant chest images

covid-19 is a condition caused by a coronavirus (called sars-cov-2) that was first identified in late 2019. in 2020, the virus has spread to many countries around the world and neither a vaccine against the virus or specific treatment for covid-19 has yet been developed. recent theory showed that the severe respiratory manifestations could be due to iron toxicity which cause intense inflammation in the alveoli and hence the ground glass appearance that was seen in ragdiology imaging objective : to evaluate the efficacy of using desferal injections for prevention of ards in moderate cases with fever , chest tightness and relevant chest images randomisation: participants are randomly allocated to either standard care or standard care plus desferal injection. randomization will be done through computer generated list by principal investigator. allocation will be determined by block randomisation, stratified by hospital. this will be carried out by an independent statistician, prior to the trial commencement, using stata (statacorp, college station, tx, usa) to generate the allocation sequence. allocations will be concealed within sequentially numbered, sealed opaque envelopes, prepared by two research assistants who are independent of the trial blinding this study will be single blind. doctors will not be blinded to intervention allocation due to lack of feasibility sample size: two hundred participants randomized into two groups each 100 individuals. the trial will begin as a 1:1 randomised trial intervention model parallel assignment desferal group an initial dose of 1000 mg should be administered at a rate not to exceed 15 mg/kg/hr. this may be followed by 500 mg over 4 hours for two doses. depending upon the clinical response, subsequent doses of 500 mg may be administered over 4-12 hours. the total amount administered should not exceed 6000 mg in 24 hours placebo group will receive glucose 5% over 4 hrs infusion standard care :- including clexan 40, antibiotics, corticosteroids ( as anti-inflammatory agent) and hydroxychloroquine

Eligibility criteria:
inclusion criteria: * patients positive for covid 19 admitted to hospital with chest tightness exclusion criteria: * pregnancy * breastfeeding * known severe hepatic impairment * known severe renal impairment * known porphyrias * diabetes mellitus * known g6pd deficiency * known myasthenia gravis * known severe psoriasis * known severe neurological disorders (especially those with a history of epilepsy - may lower seizure threshold)
nitric oxide to treat pulmonary embolism

Conditions: Pulmonary Embolism

Summary: this is a randomized study to treat subjects diagnosed with pulmonary embolism with inhaled nitric oxide or placebo (oxygen).

this is a randomized, double blind study to treat subjects diagnosed with pulmonary embolism with inhaled nitrix oxide. in this clinical trial investigators will randomized patients to receive inhaled nitric oxide or sham (nitrogen + oxygen) for 24 hours. patients must have a submassive pulmonary embolism (pe) and evidence of right ventricular (rv) heart dysfunction. investigators hypothesize that the administration of inhaled no + oxygen to patients with severe submassive pe will improve rv function, reduce rv strain and necrosis and improve dyspnea (difficulty breathing) more than sham oxygen treatment.

Eligibility criteria:
inclusion criteria: * age \>/= 18 * pulmonary imaging-proven pe, as interpreted by local radiologist * at least one predictor of rv dysfunction: 1. echocardiography with rv dilation or hypokinesis, 2. estimated rvsp \>40mm hg, 3. rv\>lv on ctpa, 4. elevated troponin i (\>0.1 ng/ml) or natriuretic peptide (bnp \> 90 pg/ml), 5. screening bedside cardiac ultrasound with color flow capability that shows rv dysfunction, 6. rv strain on ecg * plan to admit to a bed with telemetry capability exclusion criteria: * vasopressor support at time of enrollment * pregnancy * plan by clinical care team to use lytic or surgical embolectomy * plan by clinical team to use platelet inhibiting drugs * contraindication to anticoagulation * altered mental status such that the patient is unable to provide informed consent * inability to use a nasal cannula or face mask * comfort care measures instituted * supplemental oxygen requirements greater than can be administered via nasal cannula in order to maintain sa)2 \> 80% * pneumothorax with decompression * serum methb \> 10% * recent use of drugs known to increase cgmp * use of nitroprusside or nitroglycerin within the last 4 hours * use of any other nitrates with in the past 24 hours * use of a fibrinolytic medicine within the past 14 days

Keywords: pulmonary embolism clot
liposomal amikacin inhalation in m.abscessus patients

Conditions: M.Abscessus Pulmonary Disease

Summary: mycobacterium abscessus is one of the many species of non-tuberculous mycobacteria. m. abscessus infections are known to be common in patients with cystic fibrosis (cf). mycobacterium abscessus yields poor cure rates. liposomal amikacin inhalation (lai) might be a good alternative for intravenous treatment as the first results with mycobacterium avium treatment yield good results. the objective of this study is to summarize the clinical data of patients with m.abscessus treated with lai on compassionate use basis to assess treatment outcomes


Eligibility criteria:
inclusion criteria: in order to be eligible to participate in this study, a subject must meet all of the following criteria: * ats diagnostic criteria for m.abscessus pulmonary disease * \> 12 years * patients with cf/copd or other underlying disease * lai use for more than 3 weeks exclusion criteria a potential subject who meets any of the following criteria will be excluded from participation in this study: • extra-pulmonary or disseminated disease
diurnal evaluation of osa upper airway collapsibility and muscle responsiveness

Conditions: Obstructive Sleep Apnea

Summary: in the framework of pathophysiological trait in obstructive sleep apnea (osa) patients, a simplified method is proposed to measure upper airway (ua) collapsibility and muscle responsiveness during wakefulness.


Eligibility criteria:
inclusion criteria: * obstructive sleep apnea (osa) * at home-polygraphy with at least one eeg channel (psg) reporting moderate-to severe obstructive sleep apnea (apnea-hypopnea index \>14). exclusion criteria: * osa treatment ongoing during two weeks before psg * unstable cardio-respiratory disease in the 3 months before enrollment * subjects in o2 treatment

Keywords: collapsibility of upper airways muscle responsiveness
aino ecg ambulatory study

Conditions: Arrhythmias, Cardiac; Atrial Fibrillation and Flutter

Summary: the study includes collection of data from patients referred to a therapeutic evaluation in tays sydänkeskus oy (heart center co, tampere university hospital) or another unit of sydänkeskus (hereafter the heart hospital) due to suspected cardiac arrhythmia. data collection takes place outside the hospital in normal daily conditions. the monitoring is started during the outpatient visit at heart hospital polyclinic or when leaving home from cardiac ward and it continues for 2 days. reference information about the occurrence of arrhythmia episodes and the reference ecg data are obtained from simultaneously worn holter device. during the two days the study device and the reference device are worn continuously. wearing the devices does not affect the daily routines of the participant except there is no possibility to take a shower. the arrhythmia episodes are labelled in post-hoc signal analysis and annotations visually confirmed by a cardiologist. the participants are instructed to take ecg recordings with the wrist device every time the device gives a notification and also whenever the participant feels arrhythmia symptoms. there will be at least four intermittent ecg records taken on each day.


Eligibility criteria:
inclusion criteria: * age: ≥ 18 years * suspected or earlier diagnosed episodic cardiac arrhythmia, for example atrial fibrillation or atrial flutter * ability to give informed consent * volunteering for the study exclusion criteria: * implanted permanent pacemaker * inability to give informed consent e.g. due to mental confusion * denial
effect of pnf on selective motor control and balance in cp

Conditions: CP (Cerebral Palsy)

Summary: cerebral palsy is attributed to non-progressive disturbances that occurred in the developing infant brain or fetal characterized by abnormalities of muscle tone, movement and motor skills. pnf technique is thought to have an impact on voluntary motor control and balance through stimulation of proprioceptors, so the aim of this study is to determine the effects of proprioceptive neuromuscular facilitation technique on selective motor control and balance on children with cerebral palsy.

a case study was conducted in 2021 to determine the effects of pnf training for improving lower limb coordination in 7 years old cerebral palsy child. after the intervention, significant improvement is seen in gait parameters, balance, and gross motor functional classification score. a case report was conducted in 2020, to determine the effectiveness of pnf technique in improving lower extremity function in spastic diplegic cerebral palsied adolescent. patient was treated with tone inhibitory and movement facilitatory techniques. there was significant change in balance and lower extremity function before and after the treatment. there are multiple impairments in spastic cerebral palsy children; the inability to perform purposeful voluntary movements is a critical factor in determining functional ability of children. since selective voluntary motor control is an important factor that must be achieved in cerebral palsy children, pnf may be considered as a technique to gain selective voluntary control and balance proving an important intervention for cerebral palsy children.

Eligibility criteria:
inclusion criteria: * children diagnosed as spastic diplegic cerebral palsy * age between 5-12 years and both genders. * gross motor function level ii and iii according to gross motor functional classification scale (gmfcs). * spasticity range between 1 and 1+ grade according to modified ashworth scale * children who are able to follow simple verbal instructions exclusion criteria: * children with uncontrolled epilepsy * children who show no cooperation * children receiving botulinum toxin injections or surgery no earlier than 6 months before project starts. * subjects with presence of shortening or deformities of lower limb

Keywords: proprioceptive neuromuscular techniques selective voluntary motor control balance
a study to evaluate the effectiveness and safety of treatments, either alone or in combination, for the treatment of moderate to severe atopic dermatitis

Conditions: Atopic Dermatitis

Summary: atopic dermatitis (ad) is a skin condition that may cause a rash and itching due to inflammation of the skin. the purpose of this study is to evaluate the clinical efficacy and safety of single therapies and/or combination therapies for moderate to severe ad through multiple substudies. this study will consist of multiple sub-studies, sub-study 1 will have a randomized, placebo controlled period 1 followed by a lutikizumab treatment period 2 enrolling 80 participants at a 1 to 1 ratio. in sub-study 1, participants will receive subcutaneous (sc) injections of lutikizumab or matching placebo every other week for 16 weeks followed by an additional 32 weeks of subcutaneous (sc) injections of lutikizumab every other week for a total of 52 weeks. there may be higher treatment burden for participants in this trial compared to their standard of care. participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and biomarker collections.


Eligibility criteria:
inclusion criteria: * diagnosis of ad with onset of symptoms at least 1 year prior to the baseline visit and participant meets hanifin and rajka criteria. * participant has applied non-medicated, additive-free bland emollient twice daily for at least 7 days before the baseline visit. * history of inadequate response to topical corticosteroids (tcs), topical calcineurin inhibitors (tci), or topical jak inhibitors, or systemic treatment for ad, or participants for whom topical treatments are otherwise medically inadvisable (e.g., because of important side effects or safety risks). exclusion criteria: * use of the following ad treatments within the specified washout period prior to the baseline visit: -- systemic therapy for ad, including but not limited to corticosteroids, methotrexate, cyclosporine, azathioprine, phosphodiesterase type 4 (pde4) inhibitors, ifn-γ, and mycophenolate mofetil within 5 half-lives \[if known\] or within 4 weeks, whichever is longer; -- any biologic treatments, (within 5 half-lives \[if known\]) or within 12 weeks (whichever is longer), or as specified below: \< 8 weeks for dupilumab; \< 12 weeks for nemolizumab; \< 16 weeks for tralokinumab and lebrikizumab. * phototherapy treatment, laser therapy, tanning booth, or extended sun exposure that could affect disease severity or interfere with disease assessments within 4 weeks. * herbal treatments (e.g., traditional chinese medicines) within 4 weeks. * topical treatments (with the exception of non-medicated, additive-free bland emollients), including but not limited to tcs, tcis, or topical pde-4 inhibitors within 7 days. * topical jak inhibitor within 14 days. * systemic jak inhibitor (including but not limited to ruxolitinib, tofacitinib, baricitinib, upadacitinib, abrocitinib \[pf-04965842\], and filgotinib) within 5 half-lives \[if known\] or within 14 days, whichever is longer.

Keywords: lutikizumab, abt-981
warfarin versus aspirin in patients with atrial fibrillation and chronic kidney disease

Conditions: Atrial Fibrillation; Chronic Kidney Disease

Summary: in this study, the investigators examine whether aspirin or warfarin is useful for atrial fibrillation patients with chronic kidney disease.

randomised open labelled prospective study we enroll patients with chads2 score 1 non-valvular af with chronic kidney disease, and analyze all thromboembolic event or major bleeding event during follow-up period. warfarin group take dose adjusted warfarin (target inr 2.0-3.0) and aspirin group take aspirin 100mg daly. thromboembolic events: ischemic stroke or systemic arterial occlusion major bleeding: gastrointestinal bleeding or intracranial bleeding (code 430, code 431, code 432 by icd-9-cm codes) -\> only the first event of each case will be used for the analysis

Eligibility criteria:
inclusion criteria: * chads2 score 1 nonvalvular atrial fibrillation patients with chronic kidney disease exclusion criteria: * has-bled ≥30 * history of syncope or seizure within 1 year * history of major bleeding event within 6 months * bp\>180/100 * abnormal prothrombin time * hypersensitivity of aspirin or warfarin * folstein mini mental state examination score \<26 * taking or had taken other anticoagulants

Keywords: warfarin aspirin
agn-199201 for the treatment of erythema with rosacea

Conditions: Rosacea; Erythema

Summary: this study will evaluate the safety and efficacy of 3 doses of agn-199201 once and twice daily compared to vehicle for the treatment of moderate to severe facial erythema associated with rosacea.


Eligibility criteria:
inclusion criteria: * redness of the skin caused by rosacea exclusion criteria: * ≥3 inflammatory lesions * laser light-source or other energy based therapy in the last 6 months * any prescription or over the counter product for the treatment of acne or rosacea in the last 14 days
efficacy and safety study for the treatment of dysfunctional uterine bleeding

Conditions: Metrorrhagia

Summary: the purpose of this study is to determine whether the study drug is safe and effective in the treatment of dysfunctional uterine bleeding.

the study has previously been posted by schering ag, germany. schering ag, germany has been renamed to bayer healthcare ag, germany. bayer healthcare ag, germany is the sponsor of the trial.

Eligibility criteria:
inclusion criteria: * women 18 years or older * and with a diagnosis of dysfunctional uterine bleeding without organic pathology * and with at least one of the following symptoms: prolonged, frequent or excessive bleeding. exclusion criteria: * the use of steroidal oral contraceptives, or any drug that could alter oral contraception metabolism will be prohibited during the study. * women with a history of endometrial ablation or dilatation and curettage within 2 months prior to study start will be excluded.

Keywords: dysfunctional uterine bleeding
effect of cilostazol on carotid atherosclerosis estimated by 3d ultrasound in patients with type 2 diabetes

Conditions: Type 2 Diabetes Mellitus; Carotid Atherosclerosis

Summary: to investigate the effect of cilostazol compared with aspirin on carotid atherosclerosis in patients with type 2 diabetes mellitus


Eligibility criteria:
inclusion criteria: * age between 30 and 80 years * patients with type 2 diabetes on treatment (hba1c 6.0-11.0%) * carotid plaque on 3d ultrasound exclusion criteria: * acute bleeding or bleeding tendency * diagnosed with heart failure * suggestive of ischemia on ecg * uncontrolled hypertension * recently diagnosed with peptic ulcer disease * taking other antiplatelet agents * hypersensitivity to salicylic acid * aspirin induced asthma * severe kidney, liver, heart disease